Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia

Randomized Controlled Trial

doi: 10.1007/s00787-009-0042-7. Epub 2009 Jul 1.

Nikolay N Zavadenko, Natalia B Jarkova, Alexandr A Yarosh, Victoria O Soldatenkova, Leonid M Bardenstein, Irina A Kozlova, Nikolay G Neznanov, Olga I Maslova, Andrey S Petrukhin, Nina K Sukchotina, Valeriy P Zykov

Affiliations

PMID: 19568826
DOI: 10.1007/s00787-009-0042-7

Randomized Controlled Trial

Ferenc Martenyi et al. Eur Child Adolesc Psychiatry. 2010 Jan.

Abstract

The objective of the study was to compare the efficacy and tolerability of once-daily atomoxetine (< or =1.8 mg/(kg day) with those of placebo in children and adolescents (aged 6-16 years) with attention-deficit/hyperactivity disorder [ADHD (DSM-IV)]. This randomized, placebo-controlled, double-blind trial was conducted in Russia. The primary efficacy measure was baseline-to-end point changes in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored (ADHDRS-IV-Parent:Inv) total score. Tolerability measures included treatment-emergent signs and symptoms (TESS), laboratory values and weight. Compared with patients in the placebo group (n = 33), patients treated with atomoxetine (n = 72) with a mean final dose of 1.4 mg/kg showed significantly greater improvement in ADHDRS-IV-Parent:Inv total score (least-squares mean: atomoxetine, -15.8; placebo, -11.4; p = 0.013). The most common TESS in the atomoxetine group included anorexia [atomoxetine, n = 13 (18.1%); placebo, n = 2 (6.1%)], somnolence, n = 11 versus n = 3 (15.3% vs. 9.1%, respectively), abdominal pain n = 9 versus n = 1 (12.5% vs. 3.0%, respectively) and nausea, n = 8 versus n = 1 (11.1% vs. 3.0%, respectively). Seven patients in the atomoxetine group and two in the placebo group experienced clinically important weight loss during the study (> or =7% from baseline; mean change, kg: atomoxetine, -0.6; placebo, 0.1; p = 0.032). Atomoxetine is efficacious in improving ADHD symptoms in children and adolescents. Atomoxetine treatment may be associated with a numerically higher incidence of anorexia, somnolence, abdominal pain and nausea, as well as statistically greater losses in body weight.

PubMed Disclaimer

Cited by

Advances in understanding and treating ADHD.
Antshel KM, Hargrave TM, Simonescu M, Kaul P, Hendricks K, Faraone SV. Antshel KM, et al. BMC Med. 2011 Jun 10;9:72. doi: 10.1186/1741-7015-9-72. BMC Med. 2011. PMID: 21658285 Free PMC article. Review.
A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy.
Sohn M, Talbert J, Moga DC, Blumenschein K. Sohn M, et al. Atten Defic Hyperact Disord. 2016 Sep;8(3):149-58. doi: 10.1007/s12402-016-0198-1. Epub 2016 May 3. Atten Defic Hyperact Disord. 2016. PMID: 27143026 Free PMC article.
The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research.
Savill NC, Buitelaar JK, Anand E, Day KA, Treuer T, Upadhyaya HP, Coghill D. Savill NC, et al. CNS Drugs. 2015 Feb;29(2):131-51. doi: 10.1007/s40263-014-0224-9. CNS Drugs. 2015. PMID: 25698145 Review.
Efficacy and safety of atomoxetine in the treatment of children and adolescents with attention deficit hyperactivity disorder.
Kohn MR, Tsang TW, Clarke SD. Kohn MR, et al. Clin Med Insights Pediatr. 2012 Nov 5;6:95-162. doi: 10.4137/CMPed.S7868. Print 2012. Clin Med Insights Pediatr. 2012. PMID: 23641171 Free PMC article.
Patient characteristics associated with treatment initiation among paediatric patients with Attention-Deficit/Hyperactivity Disorder symptoms in a naturalistic setting in Central Europe and East Asia.
Hong J, Novick D, Treuer T, Montgomery W, Haynes VS, Wu S, Haro JM. Hong J, et al. BMC Psychiatry. 2014 Oct 30;14:304. doi: 10.1186/s12888-014-0304-x. BMC Psychiatry. 2014. PMID: 25358916 Free PMC article. Clinical Trial.

References

1. Pediatrics. 2004 Jul;114(1):e1-8 - PubMed
1. Zh Nevropatol Psikhiatr Im S S Korsakova. 1988;88(8):97-101 - PubMed
1. J Am Acad Child Adolesc Psychiatry. 2006 Aug;45(8):919-927 - PubMed
1. World Psychiatry. 2003 Jun;2(2):104-13 - PubMed
1. Am J Psychiatry. 2008 Jun;165(6):721-30 - PubMed

Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia - PubMed (original) (raw)